The startup is developing “modified DNA” therapies it claims can combine the strengths of multiple approaches, from messenger ...

The promise of a better pan-RAS inhibitor Erasca has been described as the poor man’s Revolution Medicines. Impoverished ...

This week on "The Readout LOUD": a CAR-T biotech's dramatic turnaround, and drugmakers' tactics to drive more scripts. Listen ...

If biotech funding continues to increase this year, Danaher could benefit.

Discover the best biotech ETFs to diversify your portfolio, gain exposure to cutting-edge biotech innovations, and reduce risk in a volatile sector.

But in the last three years, the company has sought to leverage its footholds in China and the U.S. to become a multinational ...

The high-profile obesity drug developer priced the biotech sector’s biggest offering in years and will use the proceeds to ...

The deal for Kelonia Therapeutics is valued at $3.25 billion upfront.

On February 16, Franklin Equity said the biotechnology industry has entered 2026 on a firmer footing following an extended ...

Doubling survival in pancreatic cancer, a long-fought rare disease approval, a massive IPO and ambitious biotech ...

Introducing CPC Biotech - one brand uniting critical fluid management components New brand unites CPC’s Biopharma connector ...

The increase in nationwide vacancy to 23.2% is a reversal from the slight dip to end 2025, according to preliminary CBRE data ...